Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
mLOWER
1 other identifier
observational
10,000
1 country
34
Brief Summary
Patients with lung nodules may develop a variety of potentially severe symptoms. These symptoms may impact a patient's quality of life and lead to difficult treatment. Through this research program, the investigators want to understand the pathogenesis of the changes of these symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2015
Longer than P75 for all trials
34 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2015
CompletedFirst Submitted
Initial submission to the registry
October 27, 2015
CompletedFirst Posted
Study publicly available on registry
February 26, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedAugust 7, 2018
August 1, 2018
10 years
October 27, 2015
August 6, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To compare the diagnostic accuracy among different type of lung nodules.
Utilizing the professional statistical software (SPSS 15.0), through T-test, Mann-Whitney U test, and analyzing the receiver operating characteristic (ROC) curve, to compare the diagnostic accuracy among different type of lung nodules. A p\<0.05 cutoff will be the standard used to determine statistical significance.
10 years
Interventions
Completed the installation and registration of mobile terminal software online
Eligibility Criteria
Approximately 10,000 patients will participate in this research program, in 100 different medical institutions.
You may qualify if:
- Age between 18 and 90
- There is a chest lesion less than 3cm width (examined by Thin-Section CT)
- The patient or his family member owns a smartphone
- Signed informed consent
- Completed the installation and registration of mobile terminal software online
- Willing to complete a 10-year period of follow-up
You may not qualify if:
- Not equipped with a smartphone
- Cannot complete the installation or registration of smartphone application software online
- Received prior chemotherapy medications for lung cancer or received lung surgical removal treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (34)
Beijing Union Hospital
Beijing, China
General Hospital of PLA
Beijing, China
Hebei Pronvince Cangzhou City People's Hospital
Cangzhou, China
Xiaya Hospital Central South Unversity
Changsha, China
Anhui Province Chaoyang Hospital
Chaoyang, China
West China Hospital Sichuan University
Chengdu, China
No.1 Hospital Chongqing Medical University
Chongqing, China
Western East Hospital No. 3 PLA Medical University
Chongqing, China
No. 2 Hospital Dalian Medical University
Dalian, China
Guizhou Province People's Hospital
Guizhou, China
International Hospital Zhejiang University
Hangzhou, China
No. 1 Hospital Zhejiang University Medical College
Hangzhou, China
Yunnan Province Cancer Hospital
Kunming, China
Shandong Province Liaocheng City People's Hospital
Liaocheng, China
No. 2 Hospital Fujian Medical University
Quanzhou, China
Kecheng District Hospital
Quzhou, China
Shanghai Zhongshan Hospital
Shanghai, 200032, China
Minhang District Hospital Fudan University
Shanghai, China
Putuo District Central Hospital Shanghai Chinese Medical University
Shanghai, China
Ruici Clinic
Shanghai, China
No. 2 Hospital Tianjin Chinese Medical University
Tianjin, China
Weifang City No.2 People's Hospital
Weifang, China
Wudang Hospital Guiyang Medical College
Wudang, China
Wuhu City No. 2 Hopsital
Wuhu, China
No. 5 Wuxi People's Hospital
Wuxi, China
Xining Hospital No.4 PLA University
Xi'an, China
Xiamen City No.3 People's Hospital
Xiamen, China
Yantai City Taishan Hopsital
Yantai, China
Henan Province People's Hospital
Zhengzhou, China
No. 1 Hospital Zhengzhou University
Zhengzhou, China
Shandong Pronvince Zibo City Official Hospital
Zibo, China
Shandong Province Linzi District Hospital
Zibo, China
Sichuan Province Zigong City No. 1 Hospital
Zigong, China
Guizhou Province Zunyi Medical College Hospital
Zunyi, China
Related Publications (2)
Yang DW, Zhang Y, Hong QY, Hu J, Li C, Pan BS, Wang Q, Ding FH, Ou JX, Liu FL, Zhang D, Zhou JB, Song YL, Bai CX. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer. 2015 Sep 1;121 Suppl 17:3113-21. doi: 10.1002/cncr.29551.
PMID: 26331818BACKGROUNDGould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e93S-e120S. doi: 10.1378/chest.12-2351.
PMID: 23649456BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Chunxue Bai, M.D, Ph.D
Chinese Alliance Against Lung Cancer
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 27, 2015
First Posted
February 26, 2016
Study Start
October 1, 2015
Primary Completion
October 1, 2025
Study Completion
October 1, 2025
Last Updated
August 7, 2018
Record last verified: 2018-08
Data Sharing
- IPD Sharing
- Will not share